Ovarian cancer is associated with a high incidence and the highest mortality compared with other gynaecological malignancies. As ovarian carcinoma remains confined to the peritoneal cavity throughout most of its clinical course, this type of cancer is an attractive candidate for intraperitoneal (i.p.) chemotherapy (Straubinger et al., 1988; Markman, 1991; Nassander et al., 1992) . Clinical pharmacokinetic studies have demonstrated that i.p. administration results in higher concentrations of drug at the site of disease, whereas systemic plasma concentrations, and therefore systemic toxicity, remain lower than after intravenous (i.v.) administration. Local anti-tumour activity after i.p. chemotherapy may therefore be expected to be higher with lower systemic toxicity.
Intraperitoneal administration of doxorubicin (DXR), a powerful broad-spectrum antineoplastic agent, is greatly hampered by local toxicity, in particular dose-limiting peritonitis. Therefore, investigators did not continue to use DXR for i.p. chemotherapy of ovarian carcinoma (Ozols et al., 1982; Deppe et al., 1985; Markman et al., 1989) . Preclinical and clinical evidence shows that the local inflammatory reaction produced by DXR is reduced by encapsulation of DXR in liposomes (Forssen and Tokes, 1981; Delgado et al., 1989) . In a phase I/II trial it was shown that DXR-liposomes can be administered i.p. with minimal peritonitis up to a three times higher dose per cycle than free DXR (Delgado et al., 1989) . Even then, maximum tolerable dose was not reached with DXR-liposomes.
Earlier, we and others have shown that the use of antibodies to direct drugs encapsulated in liposomes to tumours creates an interesting possibility for increasing the specificity and efficacy of i.p. chemotherapy of tumours located in the peritoneal cavity (Straubinger et Singh et al., 1991; Nassander et al., 1992) . To target the liposomes specifically to the tumour cells present in the peritoneal cavity, Fab' fragments of the monoclonal antibody OV-TL3, which is directed against the antigen OA3 present on over 90% of all human ovarian carcinomas, were coupled to the surface of the liposomes. When administered i.p., such OV-TL3-immunoliposomes bind rapidly and efficiently (more than 80% of the injected i.p. dose) to human ovarian cancer cells located in the peritoneal cavity of nude mice (Nassander et al., 1992) .
The aim of this study was to investigate whether immunoliposome-mediated targeting of DXR to ovarian cancer cells translates into an enhanced anti-tumour effect compared with non-targeted DXR-liposomes (lacking the antibody). Target cell binding and anti-tumour activity of DXR-immunoliposomes were studied in vitro and in vivo. The i.p. growing NIH:OVCAR-3 tumour was chosen for in vivo evaluation as this model has many features in common with clinical disease, including development of abdominal disease, ascites formation and expression of the tumour-associated antigen OA3 (Hamilton et al., 1984; Poels et al., 1986; Moseley et al., 1988; Boerman et al., 1990) . This is the first report describing the in vivo anti-tumour activity of DXRimmunoliposomes in a xenograft model of i. 
Monoclonal antibody
The murine monoclonal antibody OV-TL3 is directed against the OA3 antigen, present on over 90% of all human ovarian carcinomas (Poels et al., 1986; Boerman et al., 1990; Massuger et al., 1991) . F(ab')2 fragments of OV-TL3 were incubated with 20 mm DTT in acetate buffer at pH 5.5 (100 mM sodium acetate, 63 mM sodium chloride, 1 mM EDTA) for at least 90 min at room temperature (Nassander et al., 1995) . DTT was removed by applying the incubation mixture onto a Sephadex G-25M column (PD-10; Pharmacia, Woerden, The Netherlands). Elution occurred with acetate buffer pH 6.5 (100 mM sodium acetate, 40 mM sodium chloride, 1 mM EDTA, deoxygenated and flushed with nitrogen before use). Fab' fragments appearing in the void volume were used immediately for covalent attachment to freshly prepared liposomes containing the anchor molecule N-[4-(p-maleimidophenyl)butyryl] phosphatidylethanolamine (MPB-PE).
Preparation of immunoliposomes MPB-PE was synthesised, purified and analysed as described above (Martin and Papahadjopoulos, 1982; Nassander et al., 1995) . MPB-PE was The liposomes were loaded with DXR by creating an ammonium sulphate gradient as described recently (Haran et al., 1993) . After extrusion, the external medium of the liposomes was replaced by a glucose (0.2 M)-sodium chloride (37.5 mM) solution using ultracentrifugation (100 000xg, 45 min). Then, liposomes were incubated with DXR for 30 min at 40°C (incubation conditions 15 Himol total lipid (TL) per ml; 1 mg DXR ml-1; 1 mM desferal). Nonencapsulated DXR was removed using the cation exchange resin Dowex 50WX-4 (Storm et al., 1985) . The liposomes were centrifuged (100 000 x g, 30 min) and the pellet was redispersed in acetate buffer pH 6.5. The freshly prepared DXR-liposomes containing the anchor molecule MPB-PE were mixed with freshly prepared Fab' fragments (concentrations during incubation ranged from [6] [7] [8] [9] [10] [11] [12] For viscosity and refractive index the values of pure water were used. As a measure of the particle size distribution of the dispersion, the system reports a polydispersity index. This index ranges from 0.0 for an entirely monodisperse up to 1.0 for a polydisperse dispersion.
Tumour cell line
The human ovarian cancer cell line NIH:OVCAR-3 originated from Dr TC Hamilton (Hamilton et al., 1983 , National Cancer Institute, Bethesda, MD, USA). The NIH:OVCAR-3 cells were maintained in DMEM supplemented with heat-inactivated FCS (10%), glutamine (2 mM), penicillin (100 units ml-'), streptomycin (100 jug ml-') and amphotericin B (0.26 ,ug ml-1).
In vitro cell growth inhibition In vitro cell growth inhibition was determined by the SRB assay which involves the measurement of cellular protein, using the dye sulforhodamine-B (SRB) (Rubinstein et al., 1990; Skehan et al., 1990) . Briefly, ovarian tumour cells cultured as monolayers were treated with trypsin/EDTA (0.05%/0.02%) and washed with medium. Subsequently, cells (4 x I0 ml-1) were incubated in suspension for 30 min at 37°C with DXR-immunoliposomes, non-targeted DXRliposomes or free DXR. After the incubation, unbound liposomes and remaining free DXR were removed by centrifugation (500 x g, 3 min). The cell pellet was washed twice and resuspended in culture medium. Then, 4 x 104 cells per well were seeded in a flat bottom 96-well plate and cultured for 72 h at 37°C and 5% carbon dioxide. The cultures were fixed with 5% trichloroacetic acid (TCA) at 4°C for 1-2 h, washed with water and finally stained with 0.4% SRB dissolved in 1% acetic acid. After 20 min, the plates were washed with 1% acetic acid and air dried. The bound dye was dissolved in 10 mM Tris and the optical density was measured at 490 nm using a Biorad novapath microplate reader (Biorad Laboratories, Veenendaal, The Netherlands). The cytotoxic activity of DXR is expressed as relative cell growth, which is defined as the degree of cell proliferation relative to that of non-treated cells (= 100%) and is presented as IC50, i.e.the DXR concentration that induces 50% cell growth inhibition compared with non-treated cells.
Binding of DXR-immunoliposomes to ovarian cancer cells in vitro
In vitro cell binding of DXR-(immuno)liposomes was studied using DXR-liposomes containing 3H-labelled cholesteryl oleyl ether. OVCAR-3 cells were harvested as described above and incubated with the radiolabelled liposomes at 37°C for 30 or 90 min under the following conditions: 4 x 105 cells ml-', 0-0.88 jimol TL ml-' and 0-14 jig DXR ml-'. Unbound liposomes were separated from the cells by centrifugation (500 x g, 5 min). The cell pellet was washed twice with medium, mixed with 1 ml Soluene-350 (Packard) and digested at 40°C overnight. Radioactivity was measured as described above.
The amount of DXR associated with OVCAR-3 cells was studied by fluorescence analysis. OVCAR-3 cells (1 x 105 cells ml-') were incubated in suspension at 37°C for 30 min with DXR-immunoliposomes or non-targeted DXR-liposomes at a DXR concentration of 125 jig ml-'. Unbound liposomes were separated from the cells by centrifugation (500 x g, 5 min). The cell pellet was washed twice with icecold medium, resuspended in 0.5 ml 0.25% paraformaldehyde in PBS and kept on ice until fluorescence was measured. Fluorescence analysis was performed using a single laser FACScan, at a wavelength > 650 nm (Becton and Dickinson Immunocytometry Systems, Mountain View, CA, USA). Animals and tumour model NMRI athymic nude mice (Rygaard and Friis, 1974) were bred at Harlan CPB (HsdCpn:NMRI-nu, Zeist, The Netherlands). The animals were housed throughout the experiment under specified pathogen-free conditions in sterile filter-top cages. They received sterile standard food (SRM-A, Hope Farms, Woerden, The Netherlands) and acidified sterile water ad libitum. At the start of the experiment the animals were 5-10 weeks old.
The tumour cell line NIH:OVCAR-3 was propagated intraperitoneally as described earlier (Nassander et al., 1992) . At 3-week intervals ascites was harvested from the donor animals by rinsing the peritoneal cavity with plain RPMI-1640 medium. Cells were centrifuged once (500 x g, 5 min) and resuspended in plain RPMI-1640 medium at a concentration of approximately 4 x I07 vital cells ml-l (vitality determined by trypan blue dye exclusion); 0.5 ml of this cell suspension was injected i.p. per mouse. The nude mice developed a reproducibly growing ascitic tumour with only minor solid tumour growth.
In vivo anti-tumour activity Animals were treated 7 days after tumour cell inoculation with a single i.p. injection of DXR-(immuno-)liposomes at a dose of 0 -18 mg DXR kg-and 0 -330 jmol TL kg-in a volume of 0.5 ml. Three weeks after tumour cell inoculation, the animals were sacrificed and the peritoneal cavity was rinsed with PBS to collect all free-floating cells. Cells were centrifuged (500 x g, 5 min) and the pellet weight was determined. The weight of the collected tumour cells was used as a parameter for the anti-tumour response.
In vivo distribution studies Double-radiolabelled immunoliposomes were used to study the biodistribution of the immunoliposomes after i. light ether anaesthesia blood samples were drawn from the retroorbital plexus into heparinised tubes. Then, the mice were sacrificed and the peritoneal cavity was rinsed with 4 x 5 ml PBS. Samples for determination of the total amount of radioactivity present in the peritoneal cavity were drawn immediately. Subsequently, the peritoneal cell suspension was centrifuged (500 x g, 5 min) to spin down the cells. The supernatant was collected and samples were drawn to determine the amount of radioactivity present in the peritoneal cavity, not associated with tumour cells. Liver and spleen were collected and weighed. Radioactivity in blood was determined after the addition of Plasmasol (Packard) and decolorisation with 30% hydrogen peroxide at 40°C overnight. Radioactivity was assayed with Plasmasol as scintillation mixture. Blood volume was taken as 77.8 ml kg-' body weight (Wish et al., 1950 (Stein et al., 1980; Pool et al., 1982) . Figure 1 shows that immunoliposomes bound to the tumour cells to a higher extent (9.5-13-fold) than non-targeted liposomes, which showed hardly any binding. The degree of cell binding of the tumour-specific DXR-immunoliposomes increased in time and appeared to be dependent on the liposomal lipid concentration used. It was estimated that at the highest lipid concentration used about 7000 immunoliposomes were binding to one tumour cell after 90 min of incubation. A separate flow cytometry (FACS) experiment confirmed the need to have a tumour-specific antibody on the external liposome surface for obtaining cell binding. The mean fluorescence per cell was 15-fold higher after incubation of OVCAR-3 cells with DXR-immunoliposomes compared with non-targeted DXR-liposomes [mean fluorescence 1100 and 70 respectively; blank value (and empty immunoliposomes) about 20]. DXR levels might be underestimated owing to the fact that DXR-fluorescence is quenched when bound to DNA.
In vivo anti-tumour activity of DXR-immunoliposomes Stimulated by the superior cell growth inhibition observed in vitro, the anti-tumour activity of the tumour-specific DXRimmunoliposomes was tested in athymic mice bearing i.p. an ascitic OVCAR-3 tumour. Nude mice developed intraperitoneal disease after an i.p. injection of 2 x 107 OVCAR-3 cells. The OVCAR-3 cell line grew as single cells or as cell clusters in ascites. Solid tumour nodules remaining in the peritoneal cavity after collecting the ascitic cells were primarily detected in the lesser sac. As shown in Figure 2 , the total weight of the solid tumour mass was small compared with the weight of the ascitic tumour cells (over 4 g on day 21) and increased from 0.1 to about 0.4 per mouse over a 2-week period. The tumour did not invade the organs or the wall of the peritoneal cavity. No metastatic tumour growth could be detected within the liver, spleen, kidneys, intestines and lymph nodes (superior mesenteric, iliac) or in tissues outside the peritoneal cavity, e.g. lungs and the parathymic and mediastinal lymph nodes.
On day 7 after tumour cell inoculation i.p. treatment was started with DXR-liposomes with and without coupled tumour-specific OV-TL3 Fab' fragments. The anti-tumour effect was determined on day 21 after tumour cell inoculation. Untreated mice showed progressive tumour growth (Figure 3) . The dose-response study reveals a dose-dependent inhibition of tumour growth. However, no difference in anti-tumour effect between treatment with DXR-immunoliposomes and nontargeted DXR-liposomes was observed. At the lowest dose (0.67 mg DXR kg-1) examined, both types of DXR-liposomes already induced substantial tumour growth inhibition (P< 2 x 10-vs control). A nearly complete inhibition of tumour growth was obtained at dose levels > 2 mg kg-'.
Microscopic differentiation showed that when the determined tumour load was less than 0.5 g, other cells (e.g. lymphocytes) rather than viable tumour cells were responsible for the determined weight.
In vivo distribution of immunoliposomes To investigate why tumour-specific DXR-immunoliposomes are not more efficacious in vivo than non-targeted DXRliposomes, the degree of binding of immunoliposomes to the peritoneal tumour cells was determined. These experiments were performed with double-radiolabelled liposomes.
[3H]Cholesteryl oleyl ether was used as a marker of the liposomal lipid phase. In addition, ['4C]sucrose was incorporated in the internal aqueous phase to study the integrity of the liposomes. Double-radiolabelled immunoliposomes and non-targeted liposomes were administered i.p. to OVCAR-3-bearing nude mice at different times (day 7, 14 or 21) after tumour cell inoculation. On all days of examination, the cell binding of immunoliposomes was much higher compared with non-targeted liposomes (see Table I ). About 5% of the injected 3H-liposomal dose was found in spleen, liver and blood, 5 h after injection. The integrity of the liposomes with respect to release of the aqueous contents was also investigated. Release of sucrose from the liposomes will be detected as an increase in the 3H/'4C ratio of the injected liposome preparation. It was calculated that the loss of sucrose label from both immunoliposomes and non-targeted liposomes present in the peritoneal cavity was minimal (< 15%) 5 h after injection, indicating that the bilayer structure of the liposomes remained intact (results not shown). Immunoliposome-mediated doxorubicin delivery MH Vingerhoeds et al To investigate the question, whether the fate of the drug, doxorubicin, parallels the fate of the liposomes, the (immuno)liposomes were labelled with [14C]DXR and administered i.p. on day 7 after inoculation of the OVCAR-3 cells. Radioactivity associated with the tumour cells was determined 5 h and 24 h after injection. As shown in Table II Tables I and II) . This observation suggested to us that part of the tumour cellassociated 14C-DXR must be attributed to binding of 
Discussion
The study presented in this paper is concerned with the use of immunoliposomes (antibody-targeted liposomes) as carriers for doxorubicin (DXR) for i.p. chemotherapy of ovarian carcinoma. As a prelude to assessing the anti-tumour activity of DXR-containing OV-TL3 immunoliposomes towards in vivo growing human ovarian cancer cells (OVCAR-3), we first started to evaluate the cytotoxic effects and tumour-cell binding of DXR-immunoliposomes towards in vitro cultured OVCAR-3 cells. The in vitro cell growth inhibition of DXR encapsulated in immunoliposomes was far (200-fold) superior to DXR encapsulated in similar non-targeted liposomes (lacking the specific antibody fragments), and almost equalled the efficacy of the free drug. In line with these results, effective tumour cell binding was obtained with OV-TL3 DXR-immunoliposomes and not with non-targeted DXR-liposomes. The cell binding data are in the same (Hamilton et al., 1984) . The characteristics of ovarian carcinoma, i.e. it usually remains within the peritoneal cavity and rarely disseminates to distant body sites, were confirmed. In an earlier study we reported that OV-TL3 immunoliposomes bind rapidly and efficiently (over 80% of the injected dose on day 21 after tumour cell inoculation) in this xenograft model. In vivo target cell binding experiments confirmed these data and showed that the observed degree of tumour cell binding is dependent on the day of administration (i.e. the tumour load). As shown in Figure 3 , both DXR-immunoliposomes and non-targeted DXR-liposomes induced a pronounced anti-tumour effect. However, no difference in anti-tumour activity between the targeted and non-targeted formulation was observed. Thus, despite the observation of specific binding of the immunoliposomes to the tumour cells, differences in anti-tumour response exerted by the DXR-immunoliposomes and non-targeted DXR-liposomes were observed only in vitro and not in vivo. One likely explanation for this discrepancy is the occurrence of considerable drug leakage from the administered specific and non-specific DXR-liposomes induced by the peritoneal environment. Rapid, premature drug loss may have overshadowed the occurrence of specific immunoliposomemediated anti-tumour effects. Studies with radiolabelled DXR showed that practically all DXR recovered from the peritoneal cavity was associated with the tumour cells after i.p. administration of free DXR (Figure 4) . Likewise, DXR leaked from DXR-immunoliposomes or non-targeted DXR-liposomes present in the peritoneal cavity will rapidly associate with the tumour cells. The observation that the non-targeted liposomes, which show little cell binding, are able to deliver as much DXR to the target cells as the specific immunoliposomes (Table II ) strongly indicates that a large part of the liposomal DXR content is rapidly lost from the non-targeted liposomes. Considering the identical lipid composition, it is reasonable to assume that the extent of DXR leakage was similar for the targeted liposomes. Therefore, leakage and subsequent rapid association with the tumour cells is likely to explain the absence of any differences in anti-tumour response exerted by the immunospecific and non-specific DXR-liposomes and makes it difficult to discriminate between DXR anti-tumour activity induced by cell-bound and non cell-bound liposomes. The fact that differences in tumour cell growth inhibition were observed in vitro and not in vivo probably relates to the different composition of the incubation medium compared with ascites and the much shorter incubation time (30 min) compared with the long residence time in the peritoneal cavity of the mice.
Considering that the majority of the injected DXR molecules associate rapidly with the OVCAR-3 cells after i.p. injection, it is clear that the anti-tumour activity of free DXR is not easily improved by (immuno)liposome-mediated delivery. Other cytostatics with less affinity for the tumour cells should be considered as more promising candidates for immunoliposome-mediated delivery in this tumour model.
After cell binding of immunoliposomes, the encapsulated drug can enter the cell via different routes. Firstly, the immunoliposomes can be taken up by endocytosis. However, Nassander et al. (1995) showed that internalisation by these tumour cells takes place only to a low degree. Secondly, the liposomal contents can be released slowly after tumour cell binding, providing high DXR concentrations near the tumour cell surface. The results presented in this paper indicate that premature drug leakage occurring before binding of the immunoliposomes to the tumour cells plays a more important role in the mechanism of DXR uptake in this tumour model than leakage from cell-bound immunoliposomes. One way to improve the situation for DXRimmunoliposomes in this model is to prevent premature drug leakage by manipulation of the lipid bilayer composition. By the selection of phospholipids with higher phase transition temperatures, more stable DXR-liposomes can be prepared. However, the more rigid DXR-immunoliposomes were not nearly as effective as free DXR and the more fluid-type immunoliposomes used in this study (results not shown). This would indicate to us that cell-bound rigid immunoliposomes do not sufficiently release the encapsulated drug. To improve the therapeutic availability of the entrapped drug, triggered destabilisation of cell-bound rigid immunoliposomes seems a better option. After binding of stable DXR-immunoliposomes to the tumour cells and clearance of unbound DXRliposomes from the peritoneal cavity, destabilisation by, for example, raising the temperature (then temperature-sensitive liposomes should be used, e.g. Yatvin et al., 1978; Maruyama et al., 1993) , or lowering the pH (pH-sensitive liposomes, reviewed by Torchilin et al., 1993) might lead to efficient tumour cell kill. In summary, the in vitro cell growth inhibition of DXR encapsulated in OV-TL3 immunoliposomes is superior to that of non-targeted DXR-liposomes (lacking the specific antibody). In tumour-bearing nude mice, however, no difference in anti-tumour effect could be determined between targeted and non-targeted DXR-liposomes. Our results indicate that premature DXR leakage from (immuno)liposomes and subsequent DXR association with the tumour cells, explains why no significant differences in antitumour activity between DXR-immunoliposomes and nontargeted DXR-liposomes were observed. Further experiments will be focused on the in vitro and in vivo evaluation of stable, temperature-sensitive liposomes, which rapidly release their contents upon raising the temperature to about 42°C. Abbreviations CHOL, cholesterol; DMEM, Dulbecco's modified Eagle's medium; DTT, dithiothreitol; DXR, doxorubicin; EPC, egg-phosphatidylcholine; EPG, egg-phosphatidylglycerol; FCS, fetal calf serum; Hepes, 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid; butyryl] phosphatidylethanolamine; PBS, phosphate-buffered saline; PE, phosphatidylethanolamine; SRB, sulforhodamine-B; TCA, trichloroacetic acid; TL, total lipid (phospholipid + cholesterol).
